1. Home
  2. NVRI vs PRME Comparison

NVRI vs PRME Comparison

Compare NVRI & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enviri Corporation

NVRI

Enviri Corporation

HOLD

Current Price

$20.65

Market Cap

582.1M

Sector

Miscellaneous

ML Signal

HOLD

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$3.08

Market Cap

553.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVRI
PRME
Founded
1853
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Medicinal Chemicals and Botanical Products
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
582.1M
553.2M
IPO Year
2026
2022

Fundamental Metrics

Financial Performance
Metric
NVRI
PRME
Price
$20.65
$3.08
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$7.56
AVG Volume (30 Days)
255.4K
2.6M
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
18.18
EPS
N/A
N/A
Revenue
N/A
$4,632,000.00
Revenue This Year
$3.87
$7.06
Revenue Next Year
$3.70
$47.01
P/E Ratio
N/A
N/A
Revenue Growth
N/A
55.28
52 Week Low
$11.15
$2.67
52 Week High
$24.20
$6.94

Technical Indicators

Market Signals
Indicator
NVRI
PRME
Relative Strength Index (RSI) 39.60 42.75
Support Level $20.27 $2.73
Resistance Level $23.68 $3.72
Average True Range (ATR) 0.77 0.22
MACD -0.24 -0.06
Stochastic Oscillator 6.11 20.29

Price Performance

Historical Comparison
NVRI
PRME

About NVRI Enviri Corporation

Enviri Corp provides environmental and operational solutions to the metal and rail industries. It is based in Philadelphia, Pennsylvania, and operates in more than 30 countries. The company leverages industrial expertise to help customers improve operational performance, recover value from byproducts, enhance sustainability, and maintain critical infrastructure. Its divisions are Harsco Environmental and Harsco Rail, which combine deep operational capabilities with technologies and world-wide scale to deliver long-term value for customers, communities, and shareholders.

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Share on Social Networks: